



# Pharmacy Grand Rounds

200 First Street SW  
Rochester, Minnesota 55905  
<https://ce.mayo.edu/node/86028>

## A Second and Third Look at TKI Management in CML

### ACPE Universal Activity Number (UAN):

JA0000238-0000-20-028-L01-P

**Session Date:** 01/28/2020

**Session Time:** 11:00 – 11:45 AM (CST)

**Session Type:** Knowledge-based

**Session Fee:** Free for Mayo Clinic staff

**CE Credit Types:** A maximum of 0.75 contact hour (0.075 CEU) for the following:

- AAPA Category 1 CME Credits
- ACPE
- *AMA PRA Category 1 Credits™*
- ANCC

### Target Audience

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including: pharmacists, RNs, APRNs, PAs, MDs.

### Activity Overview

The FDA approval of imatinib in 2001 revolutionized the treatment of chronic myeloid leukemia (CML) by significantly improving life expectancy in this patient population. Following the approval of imatinib, second generation tyrosine kinase inhibitors (TKIs) dasatinib, nilotinib, and bosutinib and third generation TKI ponatinib, also found their place in CML treatment. This presentation will review the safety and efficacy profiles of each of these drugs along with unique aspects of their management. Understanding the potential negative effects on quality of life due to adverse effects, pill burden, and financial toxicities in a patient taking a TKI for long-term management of CML, current National Comprehensive Cancer Network (NCCN) guidelines emphasize the safety of TKI discontinuation in certain patients. This presentation will also review the data regarding discontinuation of TKIs, assist in identifying appropriate patients for TKI discontinuation, and discuss TKI withdrawal syndrome.

### Learning Objectives

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Compare the safety and efficacy profiles of the tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia.
2. Review the data supporting tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
3. Develop an understanding of which patients are appropriate to consider for tyrosine kinase inhibitor discontinuation and the monitoring that is required following discontinuation.

## Faculty Information

Jade L. Kutzke, PharmD, BCPS  
PGY2 Oncology Pharmacy Resident  
Mayo Clinic Hospital - Rochester, MN

Dr. Kutzke earned a PharmD degree from South Dakota State University in Brookings, SD and completed PGY1 residency training at Mayo Clinic Hospital-Rochester. She is a current PGY2 Oncology Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests include hematology, oncology, and bone marrow transplant.



## Approved Provider Statement



**JOINT ACCREDITATION™**  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

### Credit Statements

#### AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### ACPE

Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.

#### ANCC

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 ANCC nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

#### AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

## Educational Format and CE Requirements

This CE session is available as a live presentation, including live webcast.

Participants must complete the following to record attendance and obtain CE credit:

1. Attend the entire session.
2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
  - a. This number is only used for receiving text messages related to tracking attendance
  - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record attendance for every session
3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor.

To track CE, please go to [NABP CPE Monitor](#).

Non-pharmacist attendees can print out a record of attendance at [ce.mayo.edu](http://ce.mayo.edu) after completing the evaluation and claiming credit.

[Live Webcast](#) - access during presentation times

[Video Recording](#) - access two weeks after session date

## Disclosure Statement

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

- Jade L. Kutzke, PharmD, BCPS
  - Declares no financial relationship(s) pertinent to this session
  - Declares off-label use of devices and medications will not be discussed during this presentation

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. Members include:

- |   |                                     |
|---|-------------------------------------|
| • Brenda Amaris                           | • Wayne Nicholson, MD, PharmD, BCPS |
| • Mary Ellen Cordes, MS, APRN, CNS, NE-BC | • Garrett Schramm, PharmD, BCPS     |
| • Michael Huckabee, MPAS, PA-C, PhD       | • Lee Skrupky, PharmD, BCPS         |

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit [ce.mayo.edu](http://ce.mayo.edu), About Us, Disclosures - or -

<https://ce.mayo.edu/content/disclosures>

## System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browsers include: Google Chrome, Firefox, Internet Explorer 10 or 11. This session is planned and coordinated by **the Department of Pharmacy, Mayo Clinic.**